Literature DB >> 9263352

Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera.

P J van Genderen1, J J Michiels.   

Abstract

Erythromelalgia is a characteristic thrombotic complication in patients with the myeloproliferative disorders, essential thrombocythemia and polycythemia vera. In this minireview, which is based on more than 20 years of clinical observations and intervention studies, the clinical manifestations, treatment, and pathogenesis of erythromelalgia are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9263352     DOI: 10.1055/s-2007-996109

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  10 in total

Review 1.  Current applications of therapeutic phlebotomy.

Authors:  Tarek Bou Assi; Elizabeth Baz
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

Review 2.  Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 3.  What is the standard treatment in essential thrombocythemia.

Authors:  Tiziano Barbui
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Erythromelalgia as a presenting manifestation in a patient with essential thrombocythemia complicating renovascular hypertension due to unilateral renal artery stenosis.

Authors:  Jin-Wuk Hur; Young-Yiul Lee; Woong-Soo Lee; Jae-Bum Jun
Journal:  Rheumatol Int       Date:  2005-03-05       Impact factor: 2.631

5.  Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.

Authors:  Jonathan S Bleeker; William J Hogan
Journal:  Thrombosis       Date:  2011-06-08

6.  Aspirin in dermatology: Revisited.

Authors:  Aditya Kumar Bubna
Journal:  Indian Dermatol Online J       Date:  2015 Nov-Dec

7.  Erythromelalgia: an uncommon presentation precipitated by aspirin withdrawal.

Authors:  Fatima Khalid; Syed Hassan; Sophia Qureshi; Waqas Qureshi; Syed Amer
Journal:  Case Rep Med       Date:  2012-07-16

8.  Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Biologics       Date:  2007-06

Review 9.  Primary erythromelalgia: a review.

Authors:  Zhaoli Tang; Zhao Chen; Beisha Tang; Hong Jiang
Journal:  Orphanet J Rare Dis       Date:  2015-09-30       Impact factor: 4.123

10.  Secondary erythromelalgia - a case report -.

Authors:  Byoung Chan Kang; Da Jeong Nam; Eun Kyoung Ahn; Duck Mi Yoon; Joung Goo Cho
Journal:  Korean J Pain       Date:  2013-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.